关键信息
-
基因名
Tet2
- 应用
-
别名
Protein Ayu17-449 (Kiaa1546)
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His-KSI
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q4JK59
-
表达区间
1810-1912aa
-
分子量
27.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
TET2 (Tet Methylcytosine Dioxygenase 2) is a member of the TET family of enzymes that play a critical role in the active demethylation of DNA, thereby influencing gene expression and cellular differentiation. Aberrant TET2 function has been implicated in various hematological malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Mutations and dysregulation of TET2 are frequently observed in these conditions, highlighting its importance in hematopoiesis and tumorigenesis. Research on TET2 recombinants has gained momentum as scientists aim to elucidate its biochemical mechanisms and interactions with other epigenetic regulators. The study of TET2 recombinant proteins provides insights into their structural and functional properties, which are critical for understanding how TET2-mediated DNA demethylation processes can influence cancer progression and treatment responses. Furthermore, advances in recombinant DNA technology allow for the generation of TET2 variants, enabling the exploration of specific mutation effects and the design of potential therapeutic approaches targeting this enzyme in malignancies. Ultimately, a deeper understanding of TET2 function through recombinant studies may pave the way for novel epigenetic therapies aimed at re-establishing normal gene expression patterns in cancer cells.
